Inovio Biomedical Corporation (AMEX: INO)Inovio Biomedical Corporation (AMEX: INO) has their focus on developing multiple DNA-based immunotherapies. The company is known as a leading developer of human applications of electroporation using brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceutical. Inovio’s DNA delivery technology has demonstrated the ability to substantially increase gene expression and immune responses from DNA vaccines. For further information, visit the Company’s web site at www.inovio.com.
- 17 years ago
QualityStocks
Inovio Biomedical Corporation (AMEX: INO)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Files Patent for Preservative-Free Ketamine Formulation
NRx Pharmaceuticals (NASDAQ: NRXP) a clinical-stage biopharma company, has filed a patent application for NRX-100,…
-
ZDKL Champions World Peace Through Trade with Decentralized Tools for Global Commerce
Investor Brand Network ZDKL, a regulation-first blockchain project, has officially launched the Peace Through Trade…
-
QualityStocksNewsBreaks – Massimo Group (NASDAQ: MAMO) Ramps Up Innovation, Logistics to Power Growth
Massimo (NASDAQ: MAMO) is making strategic moves to actively enhance its position in the powersports and…